文献速递心血管US

房间分流治疗在射血分数降低与保留的心力衰竭中差异效应的机制基础:RELIEVE-HF 试验

Mechanistic Basis for Differential Effects of Interatrial Shunt Treatment in HFrEF vs HFpEF: The RELIEVE-HF Trial.
PubMed 文献 · JACC Cardiovasc Imaging · 2025-09-15

RELIEVE-HF 试验随机 508 例心力衰竭患者接受房间分流或假手术,按射血分数分层。2 年随访中,分流治疗使射血分数降低组心力衰竭事件减少 51%,而射血分数保留组增加 69%。本分析显示,分流后射血分数降低组出现左室逆重构,射血分数保留组则右心扩大和肺动脉收缩压升高,为临床结局差异提供机制基础。

要点

  • 射血分数降低组分流后左室舒张末期和收缩末期容积中位数均降低,提示左室逆重构。
  • 射血分数保留组分流后右室、右房、下腔静脉尺寸及肺动脉收缩压均升高。
  • 射血分数保留组基线左室和右室舒张顺应性低于射血分数降低组,分流后进一步降低。

核心结论

  • 房间分流置入后,射血分数降低与射血分数保留患者左、右心重构及肺动脉收缩压的变化方向不同,为 RELIEVE-HF 中临床结局的差异提供机制基础。

研究设计与样本

  • RELIEVE-HF 随机对照试验的超声心动图分析,共 508 例心力衰竭患者随机接受房间分流或假手术,按左室射血分数≤40% 为射血分数降低组、>40% 为射血分数保留组分层。

关键影像表现/征象

  • 射血分数降低组分流组较对照组左室舒张末期容积中位数降低 11.9 mL/m2(Q1-Q3:-21.3 至 -2.5 mL/m2;P=0.01),提示左室逆重构。
  • 射血分数降低组分流组较对照组左室收缩末期容积中位数降低 8.9 mL/m2(Q1-Q3:-17.2 至 -20.7 mL/m2;P=0.01)。
  • 射血分数保留组分流组较对照组右室、右房和下腔静脉尺寸增加,肺动脉收缩压升高 4.7 mm Hg(Q1-Q3:0.9-8.5 mm Hg;P=0.02)。
  • 射血分数保留组基线左室和右室舒张顺应性低于射血分数降低组,分流治疗后进一步降低。
  • 射血分数降低组分流组右室、右房、下腔静脉尺寸及肺动脉收缩压无显著变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: The RELIEVE-HF (REducing Lung congestion symptoms using the v-wavE shunt in adVancEd Heart Failure) trial randomized 508 patients with heart failure (HF) to interatrial shunt treatment vs placebo procedure. Randomization was stratified into 2 patient groups: heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction [LVEF] ≤40%); and heart failure with preserved ejection fraction (HFpEF) (LVEF >40%). HF event rates (all-cause death, transplantation or left ventricular (LV) assist device, HF hospitalization or outpatient worsening) after shunt treatment during 2-year follow-up were directionally opposite: decreased by 51% in HFrEF, increased by 69% in HFpEF.

OBJECTIVES: This study aims to examine differences in cardiac structure and function before and after interatrial shunt placement in patients with HFrEF vs HFpEF that could underlie these discordant clinical outcomes.

METHODS: Serial changes from baseline to 12 months in 17 transthoracic echocardiographic parameters in shunt-treated vs control patients in HFrEF vs HFpEF were assessed and compared by ANCOVA (analysis of covariance).

RESULTS: In shunt-treated vs control patients with HFrEF, there were reductions in median LV end-diastolic volumes (-11.9 mL/m2 [Q1-Q3: -21.3 to -2.5 mL/m2]; P = 0.01) and LV end-systolic volumes (-8.9 mL/m2 [Q1-Q3: -17.2 to -20.7 mL/m2]; P = 0.01) indicative of reverse LV remodeling. There were no significant changes in right ventricular (RV), right atrial, or inferior vena cava sizes or pulmonary artery systolic pressure (PASP). In contrast, shunt-treated vs control patients with HFpEF did not have LV remodeling, but they had increased RV, right atrial, and inferior vena cava dimensions, and PASP also increased (4.7 mm Hg [Q1-Q3: 0.9-8.5 mm Hg]; P = 0.02). LV and RV diastolic compliance were decreased in HFpEF vs HFrEF at baseline and decreased further after shunt treatment in HFpEF.

CONCLUSIONS: Differential changes in left-sided and right-sided heart remodeling and PASP following interatrial shunt placement in patients with HFrEF vs HFpEF provide a mechanistic basis for the variable effects on clinical outcomes observed in RELIEVE-HF. (REducing Lung congestion symptoms using the v-wavE shunt in adVancEd Heart Failure [RELIEVE-HF]; NCT03499236).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Zile MR, Abraham WT, Lindenfeld J, et al. Mechanistic Basis for Differential Effects of Interatrial Shunt Treatment in HFrEF vs HFpEF: The RELIEVE-HF Trial. JACC Cardiovasc Imaging. 2025. PMID: 40892630. doi:10.1016/j.jcmg.2025.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。